<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04069429</url>
  </required_header>
  <id_info>
    <org_study_id>IRB_00058734</org_study_id>
    <nct_id>NCT04069429</nct_id>
  </id_info>
  <brief_title>Radiation Dose in Humans From Orally Administered Tc99m-Heparin</brief_title>
  <official_title>Radiation Dose in Humans From Orally Administered Tc99m-Heparin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study of a new agent used for evaluation of inflammation in the GI tract.
      This agent is investigational and thus is being studied to determine appropriate dosing and
      administration in both normal controls (i.e. people without gastrointestinal complaints) and
      patients with eosinophilic disease (i.e. those with an immune reaction and inflammation in
      their bodies with a certain cell called an eosinophil).

      The study will test whether the radiolabeled agent will bind to the inflammation of
      eosinophilic esophagitis patients because an animal model of eosinophilic esophagitis which
      shows the striking deposition of eosinophil granule proteins is not available.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>dose assessment of orally administration of Tc99m-Heparin in healthy control and Eosinophilic Esophagitis patients</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biodistribution of Tc99m-heparin</measure>
    <time_frame>over approximately 24-26 hours</time_frame>
    <description>Biodistribution of Tc99m-heparin to the esophagus and other organs, especially of the gastrointestinal tract as judged by planar scans and by single photon emission computed tomography scans.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Calculation of organ doses</measure>
    <time_frame>over approximately 24-26 hours</time_frame>
    <description>Calculation of organ doses from the oral administration of Tc99m-heparin. The organ doses will be measured in miliSieverts using a computer program called OLINDA (Version 2).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">17</enrollment>
  <condition>Eosinophilic Esophagitis</condition>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 controls (subjects without GI symptoms and known GI disease), subjects will receive the radiopharmaceutical agent orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eosinophilic Esophagitis Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 patients with diagnosed EoE (greater than 15 eosinophils per HPF) on esophageal biopsy will be included as the diseased population, subjects will receive the radiopharmaceutical agent orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Computerized Tomography scan</intervention_name>
    <description>imaging scan from a person's eyes to their thighs</description>
    <arm_group_label>Eosinophilic Esophagitis Patients</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <other_name>CT scan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Single Photon Emission Computed Tomography scans</intervention_name>
    <description>imaging scan taken during, and after, the administration of the radioactive agent</description>
    <arm_group_label>Eosinophilic Esophagitis Patients</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <other_name>SPECT scans</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Technetium Tc 99M</intervention_name>
    <description>subjects are administered radioactive heparin as part of study participation.</description>
    <arm_group_label>Eosinophilic Esophagitis Patients</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <other_name>Radioactive Heparin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Planar Images</intervention_name>
    <description>2 dimensional imaging - whole body planar scans</description>
    <arm_group_label>Eosinophilic Esophagitis Patients</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Esophagogastroduodenoscopy</intervention_name>
    <description>esophagogastroduodenoscopy with tissue biopsies</description>
    <arm_group_label>Eosinophilic Esophagitis Patients</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  10 patients with diagnosed EoE (greater than 20 eosinophils per HPF) on esophageal
             biopsy will be included as the diseased population

          -  7 controls (subjects without GI symptoms and known GI disease)

        Exclusion Criteria:

          -  bleeding diathesis or contraindication to esophageal biopsies

          -  severe sleep apnea

          -  incarceration

          -  pregnancy

          -  inability to lie flat for 2 hours

          -  history of bleeding disorder

          -  Use of steroids

          -  Breast feeding

          -  Allergy to heparin or history of severe reaction to heparin

          -  allergy to mucomyst or severe asthma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald Gleich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel Douglas</last_name>
    <phone>801-213-0373</phone>
    <email>rachel.douglas@hsc.utah.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Douglas</last_name>
      <phone>801-213-0373</phone>
      <email>rachel.douglas@hsc.utah.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 27, 2019</study_first_submitted>
  <study_first_submitted_qc>August 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>October 4, 2019</last_update_submitted>
  <last_update_submitted_qc>October 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Gerald J. Gleich</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

